Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
02 2019
Historique:
received: 05 08 2018
revised: 14 11 2018
accepted: 22 11 2018
entrez: 15 2 2019
pubmed: 15 2 2019
medline: 19 11 2019
Statut: ppublish

Résumé

Several clinical and procedural factors determine outcomes after transcatheter aortic valve replacement (TAVR), but data are scarce on the impact of post-TAVR discharge disposition on long-term outcomes. We sought to analyse whether discharge location after TAVR is associated with 1-year outcomes in women undergoing contemporary TAVR. The Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry is the first all-female TAVR registry to study the safety and performance of contemporary TAVR in women (n = 1019). Information on discharge location was available in 817 patients (80.2%). We compared women discharged home vs those discharged to another location (nursing home, rehabilitation, or other hospital). One-year outcomes were adjusted using multivariable Cox regression methods with discharge home as the reference group. Of the study subjects, 75.2% (n = 614) were discharged home and 24.8% (n = 203) to another location. Women discharged to other locations were older with a greater prevalence of severe lung disease requiring home oxygen and renal failure on dialysis but were less frequently considered frail or at high surgical risk compared with women discharged home. After multivariable adjustment, non-home discharge was associated with greater hazard for 1-year Valve Academic Research Consortium 2 efficacy (21.3% vs 10.8%, hazards ratio [HR] 1.9, 95% confidence interval [CI] 1.2-2.9) and safety endpoints (31.5% vs 15.2%, HR 2.1, 95% CI 1.5-3.0), cardiovascular death (12.7% vs 5.5%, HR 2.0, 95% CI 1.1-3.6), and stroke (6.5% vs 0.8%, HR 8.5, 95% CI 2.9-25.6). In women undergoing contemporary TAVR, discharge disposition significantly affects 1-year risk of outcomes even after adjustment for recorded baseline differences. This might suggest the necessity of considering additional factors beyond comorbidities in the TAVR decision-making process.

Sections du résumé

BACKGROUND
Several clinical and procedural factors determine outcomes after transcatheter aortic valve replacement (TAVR), but data are scarce on the impact of post-TAVR discharge disposition on long-term outcomes. We sought to analyse whether discharge location after TAVR is associated with 1-year outcomes in women undergoing contemporary TAVR.
METHODS
The Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry is the first all-female TAVR registry to study the safety and performance of contemporary TAVR in women (n = 1019). Information on discharge location was available in 817 patients (80.2%). We compared women discharged home vs those discharged to another location (nursing home, rehabilitation, or other hospital). One-year outcomes were adjusted using multivariable Cox regression methods with discharge home as the reference group.
RESULTS
Of the study subjects, 75.2% (n = 614) were discharged home and 24.8% (n = 203) to another location. Women discharged to other locations were older with a greater prevalence of severe lung disease requiring home oxygen and renal failure on dialysis but were less frequently considered frail or at high surgical risk compared with women discharged home. After multivariable adjustment, non-home discharge was associated with greater hazard for 1-year Valve Academic Research Consortium 2 efficacy (21.3% vs 10.8%, hazards ratio [HR] 1.9, 95% confidence interval [CI] 1.2-2.9) and safety endpoints (31.5% vs 15.2%, HR 2.1, 95% CI 1.5-3.0), cardiovascular death (12.7% vs 5.5%, HR 2.0, 95% CI 1.1-3.6), and stroke (6.5% vs 0.8%, HR 8.5, 95% CI 2.9-25.6).
CONCLUSIONS
In women undergoing contemporary TAVR, discharge disposition significantly affects 1-year risk of outcomes even after adjustment for recorded baseline differences. This might suggest the necessity of considering additional factors beyond comorbidities in the TAVR decision-making process.

Identifiants

pubmed: 30760427
pii: S0828-282X(18)31362-X
doi: 10.1016/j.cjca.2018.11.035
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

199-207

Informations de copyright

Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Julinda Mehilli (J)

Munich University Clinic, Ludwig-Maximilians-University and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.

Jaya Chandrasekhar (J)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Samantha Sartori (S)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Alaide Chieffo (A)

San Raffaele Scientific Institute, Milan, Italy.

Anna S Petronio (AS)

AOUP Cisanello, University Hospital, Pisa, Italy.

Thierry Lefèvre (T)

Institut Hospitalier Jacques Cartier, Ramsay Générale de Santé, Massy, France.

Patrizia Presbitero (P)

Istituto Clinico Humanitas, Milan, Italy.

Piera Capranzano (P)

University of Catania, Catania, Italy.

Didier Tchetche (D)

Clinique Pasteur, Toulouse, France.

Alessandro Iadanza (A)

Azienda Ospedaliera Universitaria Senese, Policlinico Le Scotte, Siena, Italy.

Gennaro Sardella (G)

Policlinico "Umberto I", "Sapienza" University of Rome, Rome, Italy.

Nicolas M Van Mieghem (NM)

Erasmus Medical Center, Thorax center, Rotterdam, The Netherlands.

Emanuela Meliga (E)

Mauriziano Hospital, Turin, Italy.

Nicolas Dumonteil (N)

Rangueil University Hospital, Toulouse, France.

Chiara Fraccaro (C)

University of Padova, Padova, Italy.

Daniela Trabattoni (D)

Centro Cardiologico Monzino, Milan, Italy.

David Jochheim (D)

Munich University Clinic, Ludwig-Maximilians-University and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.

Magda Zadrozny (M)

Munich University Clinic, Ludwig-Maximilians-University and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.

Ghada W Mikhail (GW)

Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom.

Samin Sharma (S)

Mount Sinai Hospital, New York, New York, USA.

Maria C Ferrer (MC)

Hospital Universitario Miguel Servet, Zaragoza, Spain.

Christoph Naber (C)

Contilia Heart and Vascular Centre, Elisabeth Krankenhaus, Essen, Germany.

Peter Kievit (P)

Radboud University Nijmegen Medical Center, The Netherlands.

Kamilia Moalem (K)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Usman Baber (U)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Clayton Snyder (C)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Madhav Sharma (M)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Marie C Morice (MC)

Institut Hospitalier Jacques Cartier, Ramsay Générale de Santé, Massy, France.

Roxana Mehran (R)

Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: Roxana.mehran@mountsinai.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH